Clinical Research Directory
Browse clinical research sites, groups, and studies.
Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer
Sponsor: University of Wisconsin, Madison
Summary
The purpose of this study is to evaluate the imaging and gene expression biomarkers in prostate cancer. Participants have high-risk prostate cancer and have indicated they will undergo external beam radiation therapy, brachytherapy, and androgen deprivation therapy (EBRT+BTX+ADT). Participants can expect to be in this study for up to 5 years.
Official title: Pilot Study to Identify Radiogenomic Biomarkers to Predict Early Treatment Response to Androgen Deprivation Therapy and Radiation Therapy in High Risk Prostate Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2023-03-08
Completion Date
2027-08
Last Updated
2026-03-20
Healthy Volunteers
No
Conditions
Interventions
External beam radiation therapy
Standard of care EBRT
Prostate brachytherapy boost
Standard of care BTX
Androgen deprivation therapy
Standard of care ADT
Positron emission tomography (PET)/magnetic resonance imaging (MRI)
Pelvic PET scanning with tracer will take approximately 45 minutes. This will be followed by the injection of a contrast agent followed by whole body PET/MRI scanning which will take approximately 30 minutes.
Locations (1)
University of Wisconsin
Madison, Wisconsin, United States